Abstract：ObjectiveTo investigate the effects of Cisplatin and Pemetrexed,Recombinant Human Endostatin Injection combined with chemotherapy in the treatment of advanced lung adenocarcinoma.MethodsFrom June 2013 to June 2016,62 patients with advanced lung adenocarcinoma treated in our hospital were selected as objects,and the clinical data was analyzed.30 patients who treated with Cisplatin and Pemetrexed was the control group,32 patients who treated with Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection was the observation group.The treatment effects and adverse reactions were compared between the two groups.ResultsThe disease control rate in the observation group(87.50%)was higher than that in the control group(63.33%),and the difference was statistically significant(P＜0.05).The median tumor progression time in the observation group (8 months)was longer than that in the control group (5.5 months),and the difference was statistically significant(P＜0.05).The life quality increases efficiency were compared between the two groups,and the difference was not statistically significant(P＞0.05).The adverse reaction rate were compared between the two groups,and the difference was not statistically significant(P＞0.05).ConclusionThe treatment of Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection combined application in advanced lung adenocarcinoma,the median time to progression of the tumor was significantly prolonged,and will not increase the adverse reactions of patients.It is an effective treatment,worthy of clinical application.
京公网安备 11010502046607号